Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-PR04.MZ
- Development stage
- Unknown
- Lead developer
- Positronpharma
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
18F-PR04.MZ (also written as [18F]PR04.MZ) is a fluorine-18 labeled tropane-based small molecule radiopharmaceutical developed as a positron emission tomography (PET) imaging agent. It acts as a highly selective and high-affinity ligand for the presynaptic dopamine transporter (DAT). Developed by Positronpharma SA in collaboration with academic institutions, 18F-PR04.MZ is used as a diagnostic imaging agent to evaluate nigrostriatal neuron integrity and detect dopaminergic deficits. Its primary clinical applications include the evaluation of movement disorders, such as Parkinson's disease, and the differential diagnosis of atypical parkinsonian syndromes (e.g., multiple system atrophy and progressive supranuclear palsy) from other conditions.
- Other names
- 18PR04.MZN-4-fluorobut-2-yn-1-yl-2β-carbomethoxy-3β-phenyltropane[18F]PR04.MZ
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on 18F-PR04.MZ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-PR04.MZ.